Laboratorios Almirall gets rights to Ironwood's linaclotide in Europe; later gets rights in Mexico
Spanish pharmaco Laboratorios Almirall SA (respiratory, autoimmune, and dermatology therapeutics) received exclusive European rights to develop and commercialize Ironwood Pharmaceuticals' (mainly gastrointestinal and cardiovascular therapeutics) GI compound linaclotide.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.